Neumora Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Our corporate headquarters are located in Watertown, Massachusetts, where we sublease approximately 31,000 square feet of office and laboratory space pursuant to a sublease agreement that expires in June 2025.
In March 2021, we entered into a lease agreement for an office facility in South San Francisco, California. The term of the lease commenced in April 2021 and ended in December 2023.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.